News
fool.com · 2 days ago
Is Ginkgo Bioworks Holdings Stock a Buy?Ginkgo Bioworks has been focusing on developing its artificial intelligence capabilities to enhance its cell programming platform. The company's results, however, have been underwhelming, with sales falling by more than 50% last quarter.
fool.com · 4 days ago
4 Small-Cap Value Stocks That Could Go ParabolicSmall-cap stocks have historically responded positively to interest-rate cuts. These four small-cap equities may be poised for a bull run once the Fed eventually slashes rates.
fool.com · 5 days ago
What's the Difference Between Biotech Stocks and TechBio Stocks?Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.
prnewswire.com · 5 days ago
Ginkgo Bioworks to Participate in Two Conferences in MayBOSTON , May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. TD Cowen's 2nd Annual Sustainability Week: Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard, will participate in the virtual Sustainable API Manufacturing panel at 4:25 pm ET on May 22, 2024.
prnewswire.com · 6 days ago
Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in JapanSojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON , May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.
seekingalpha.com · 10 days ago
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2024 Earnings Call TranscriptGinkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2024 Earnings Conference Call May 9, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Mike Ryskin - Bank of America Steve Mah - TD Cowen Megan LeDuc Good evening, I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
zacks.com · 11 days ago
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Lags Revenue EstimatesGinkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago.
prnewswire.com · 11 days ago
Ginkgo Bioworks Reports First Quarter 2024 Financial ResultsGinkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 BOSTON , May 9, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
investorplace.com · 12 days ago
3 Meme Stocks to Sell in May Before They Crash & BurnThe stock market has been on an incredible run over the past year with tech and growth stocks surging. Traders have piled into many fast-moving companies in hopes of locking in quick trading gains.
investorplace.com · 13 days ago
Want $10,000? Invest $1,000 in These 3 Penny Stocks NowThere's the age-old adage, “You have to spend money to make money.” But then again, what if you could spend pennies and get back dollars?
prnewswire.com · 13 days ago
GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel SweetenerTo scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo's Plant Trait Services , Protein Services , and Deployment Capabilities JONESBORO, Ark. and BOSTON , May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.
prnewswire.com · 14 days ago
Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual MeetingBOSTON , May 6, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.
prnewswire.com · 18 days ago
Ginkgo Bioworks Announces Date of First Quarter 2024 Results PresentationPresentation and Q&A session scheduled for post-market on Thursday, May 9, 2024 BOSTON , May 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
fool.com · 20 days ago
Ginkgo Bioworks: Buy, Sell, or Hold?Ginkgo Bioworks needs to keep scaling up to increase its efficiency. The challenge is it doesn't have a very long cash runway anymore.
invezz.com · 20 days ago
Here's why Cathie Wood's Ginkgo Bioworks (DNA) stock has divedCathie Wood, the founder of Ark Invest, is under intense pressure as most of her ETFs implode. The Ark Innovation Fund (ARKK) ETF has crashed by 72% from its highest level in 2021 while the Ark Genomic Revolution ETF (ARKG) is down by 79% from the same period.
invezz.com · 20 days ago
Here's why Cathie Wood's Ginkgo Bioworks (DNA) stock has divedCathie Wood, the founder of Ark Invest, is under intense pressure as most of her ETFs implode. The Ark Innovation Fund (ARKK) ETF has crashed by 72% from its highest level in 2021 while the Ark Genomic Revolution ETF (ARKG) is down by 79% from the same period.
investorplace.com · 21 days ago
Is a Giant Short Squeeze in Ginkgo Bioworks (DNA) Stock?Ginkgo Bioworks (NYSE: DNA ) stock has seen a recent surge in short interest combined with a jump in its share price, fueling speculation that a short squeeze is in the makings for DNA stock. Indeed, over the past few days, the number of DNA short shares available has recently sunk from around 750,000 to 0, according to financial data website Fintel.
prnewswire.com · 1 month ago
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery ProductsIGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON , April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee (IGDI), an innovative international developer and provider of clean label baking ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new collaboration. IGDI has identified a new sourdough bakery strain that can improve the flavor and aroma profile of baked goods via its starter culture product, Pater ®.
fool.com · 1 month ago
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.Novo Nordisk and Ginkgo Bioworks will work together on manufacturing. Producing more obesity and diabetes medicines is likely a priority.
businesswire.com · 1 month ago
Modalis Announces Partnership with Ginkgo BioworksTOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo's global customers in the cell and gene therapy fields to access Modalis' proprietary epigenome modulation technology, CRISPR-GNDM® (Guide Nucleotide-Directed Modulation). Modalis' CRISPR-GNDM® Technology is capable of activat.